RE: October 31st hopefully is when this surges23 Oct 2024 12:26
Nissan, this is potentially a game changer. The assessment was referred to the NHSS by AINA - The Accelerated National Innovation Adoption collaborative. Emphasis being very much on 'accelerated'. If this assessment finds in favour of adopting the genotype testing then this could lead to about £1.5m in revenue in one fell swoop just for CYP2C19 tests.
About 30% of patients cannot metabolise clopidogrel and so are at risk of further strokes. there are about 13k victims of strokes and heart attacks in Scotland each year. 13,000 tests at £120 each would leave GDR without about £1m profit after costs. This publication is going to be critical to how things play out for GDR over the next year. If NHSS, like NHS in England, decides to twiddle their thumbs and keep kicking the can down the street then GDR will doubtless be bought out but for a low ball offer even before FDA approval is given.
If on the other hand NHSS is told 'go for it and...get in with it pronto' then the short term picture looks very very different for GDR.
One of the biggest fears at the moment is whether or not AIM will even exist by next Easter when GDR will need funding again. Rachel Reeves could single handedly destroy the future for all small companies wishing to grow and attract investment in the UK. The new Labour govt are so desperate to raise taxes that I can see them removing the Business Relief (BR) on AIM and thus see a vast amount of money from iis disappear over night and lead to capitulation. In her efforts to seek tax revenue RR is risking irreparable damage to the LSE and actually ending up with vastly reduced revenue and ultimately zero from AIM if it disappears altogether.